161 related articles for article (PubMed ID: 20367801)
1. Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.
Patel K; Jhaveri R; George J; Qiang G; Kenedi C; Brown K; Cates C; Zekry A; Tillmann HL; Elliott L; Kilaru R; Albrecht J; Conrad A; McHutchison JG
J Viral Hepat; 2011 May; 18(5):331-7. PubMed ID: 20367801
[TBL] [Abstract][Full Text] [Related]
2. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
3. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
6. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.
Bullano MF; Kamat S; Wertz DA; Borok GM; Gandhi SK; McDonough KL; Willey VJ
Am J Health Syst Pharm; 2007 Feb; 64(3):276-84. PubMed ID: 17244877
[TBL] [Abstract][Full Text] [Related]
8. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
Pepine CJ; Jacobson TA; Carlson DM; Kelly MT; Setze CM; Gold A; Stolzenbach JC; Williams LA
Clin Cardiol; 2010 Oct; 33(10):609-619. PubMed ID: 20960535
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
10. Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?
Milionis HJ; Gazi IF; Filippatos TD; Tzovaras V; Chasiotis G; Goudevenos J; Seferiadis K; Elisaf MS
Angiology; 2005; 56(5):585-92. PubMed ID: 16193198
[TBL] [Abstract][Full Text] [Related]
11. Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
Abe M; Maruyama N; Yoshida Y; Ito M; Okada K; Soma M
Endocr J; 2011; 58(8):663-74. PubMed ID: 21670545
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial.
Ballantyne CM; Miller E; Chitra R
Clin Ther; 2004 Nov; 26(11):1855-64. PubMed ID: 15639697
[TBL] [Abstract][Full Text] [Related]
14. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Han Y; Zhu G; Han L; Hou F; Huang W; Liu H; Gan J; Jiang T; Li X; Wang W; Ding S; Jia S; Shen W; Wang D; Sun L; Qiu J; Wang X; Li Y; Deng J; Li J; Xu K; Xu B; Mehran R; Huo Y
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):62-70. PubMed ID: 24076297
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
McKenney JM
Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
[TBL] [Abstract][Full Text] [Related]
16. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.
Saito Y; Goto Y; Dane A; Strutt K; Raza A
J Atheroscler Thromb; 2003; 10(6):329-36. PubMed ID: 15037821
[TBL] [Abstract][Full Text] [Related]
17. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
18. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
[TBL] [Abstract][Full Text] [Related]
20. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins.
Bergheanu SC; Reijmers T; Zwinderman AH; Bobeldijk I; Ramaker R; Liem AH; van der Greef J; Hankemeier T; Jukema JW
Curr Med Res Opin; 2008 Sep; 24(9):2477-87. PubMed ID: 18655752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]